What is Pharma Mar, S.A. (PHM.MC)?

Pharma Mar, S.A. (PHM.MC) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

Pharma Mar, S.A. (PHM.MC)

Stock analysis · BME · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

0.47

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Pharma Mar, S.A. (PHM.MC) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Jul 29, 2026

EPS $-0.06 vs est. $0.18

Missed by $0.23

Proprietary Signals

Signal snapshot temporarily unavailable.

About Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.